HomeCompareJIAXF vs JNJ

JIAXF vs JNJ: Dividend Comparison 2026

JIAXF yields 3.37% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JIAXF wins by $737.93M in total portfolio value
10 years
JIAXF
JIAXF
● Live price
3.37%
Share price
$4.54
Annual div
$0.15
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$737.96M
Annual income
$698,128,027.74
Full JIAXF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — JIAXF vs JNJ

📍 JIAXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJIAXFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JIAXF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JIAXF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JIAXF
Annual income on $10K today (after 15% tax)
$286.17/yr
After 10yr DRIP, annual income (after tax)
$593,408,823.58/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JIAXF beats the other by $593,404,837.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JIAXF + JNJ for your $10,000?

JIAXF: 50%JNJ: 50%
100% JNJ50/50100% JIAXF
Portfolio after 10yr
$369.00M
Annual income
$349,066,358.57/yr
Blended yield
94.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JIAXF
No analyst data
Altman Z
4.0
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JIAXF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJIAXFJNJ
Forward yield3.37%2.13%
Annual dividend / share$0.15$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$737.96M$30.3K
Annual income after 10y$698,128,027.74$4,689.40
Total dividends collected$735.06M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JIAXF vs JNJ ($10,000, DRIP)

YearJIAXF PortfolioJIAXF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,373$673.35$10,592$272.30+$781.00JIAXF
2$13,601$1,431.44$11,289$357.73+$2.3KJIAXF
3$17,753$3,199.64$12,123$472.89+$5.6KJIAXF
4$26,802$7,806.22$13,141$629.86+$13.7KJIAXF
5$50,706$22,028.46$14,408$846.81+$36.3KJIAXF
6$132,154$77,898.81$16,021$1,151.60+$116.1KJIAXF
7$520,893$379,488.21$18,122$1,588.22+$502.8KJIAXF
8$3,353,193$2,795,837.49$20,930$2,228.20+$3.33MJIAXF
9$37,228,842$33,640,924.97$24,792$3,191.91+$37.20MJIAXF
10$737,962,889$698,128,027.74$30,274$4,689.40+$737.93MJIAXF

JIAXF vs JNJ: Complete Analysis 2026

JIAXFStock

Jiangxi Copper Company Limited engages in exploring, mining, smelting, and refining copper in Mainland China, Hong Kong, and internationally. It offers copper cathodes, copper rods and wires, sulphuric acid, and other products, as well as deposit, loan, guarantee, and financing consultation services. It is involved in the processing and sale of copper and hardware electric products; production and sale of non-ferrous metals, rare metals and non-metals, electrolytic copper foil, spiral and copper tubes, copper and enameled wires, other copper pipe products, and cast iron grinding balls; provision of repair, consulting, and transportation services; exploration, mining, selection, and smelting of gold and chemical; project, industrial, and fund investment, investment management, and investment and economic information advisory services; metallurgical chemistry; equipment manufacturing and maintenance activities; and development and production of thermo-electronic semiconductors and appliances. In addition, it engages in the development of chemical technologies; contracting for mining constructions; production and sale of casting products; maintenance of mechanical and electrical equipment; installation and debugging of equipment; sale of building materials; production of copper sulfate and electrolytic copper; scrap of base metals; and geological investigation and survey, and construction and engineering measurement. Further, it is involved in the sale of mineral processing, fine chemical, and other industrial and domestic products; trading of metal products; machinery processing; manufacture and sale of wear resistant materials; and trade and settlement of import-export business, offshore investment and financing, cross-border RMB settlement, and research and development activities. The company was founded in 1979 and is headquartered in Nanchang, China.

Full JIAXF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this JIAXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JIAXF vs SCHDJIAXF vs JEPIJIAXF vs OJIAXF vs KOJIAXF vs MAINJIAXF vs ABBVJIAXF vs MRKJIAXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.